Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. (Q50913835)

25 March 2018

title

Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. (English)

1 reference

25 March 2018

1 reference

1

1 reference

25 March 2018

Alessandro Gronchi

2

1 reference

25 March 2018

Elena Rosa Fumagalli

7

1 reference

25 March 2018

Marco Fiore

11

1 reference

25 March 2018

Paolo Giovanni Casali

15

1 reference

25 March 2018

Patrick Schöffski

5

Patrick Schöffski

1 reference

25 March 2018

20

Stefan Sleijfer

1 reference

25 March 2018

Axel Le Cesne

16

Axel Le Cesne

1 reference

25 March 2018

Peter Hohenberger

3

Peter Hohenberger

1 reference

25 March 2018

Sylvie Bonvalot

4

Sylvie Bonvalot

1 reference

25 March 2018

Frits van Coevorden

24

Frits van Coevorden

1 reference

25 March 2018

Winette T A van der Graaf

22

Winette van der Graaf

1 reference

25 March 2018

Eberhard Stoeckle

18

Eberhard Stoeckle

1 reference

25 March 2018

Cornelis Verhoef

23

Cornelis Verhoef

1 reference

25 March 2018

Elżbieta Bylina

12

Elzbieta Bylina

1 reference

25 March 2018

author name string

Sebastian Bauer

6

1 reference

25 March 2018

Pawel Nyckowski

8

1 reference

25 March 2018

Buu-Phuc Nguyen

9

1 reference

25 March 2018

Jan Martijn Kerst

10

1 reference

25 March 2018

Mathias Hoiczyk

13

1 reference

25 March 2018

Annemieke Cats

14

1 reference

25 March 2018

Jürgen Treckmann

17

1 reference

25 March 2018

Johannes H W de Wilt

19

1 reference

25 March 2018

Ronald Tielen

21

1 reference

25 March 2018

publication date

13 June 2013

1 reference

25 March 2018

Annals of Surgical Oncology

published in

1 reference

25 March 2018

volume

20

1 reference

25 March 2018

issue

9

1 reference

25 March 2018

page(s)

2937-2943

1 reference

25 March 2018

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

cites work

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Surgical options for localized and advanced gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

The combination of surgery and imatinib in GIST: a reality for localized tumors at high risk, an open issue for metastatic ones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Surgical considerations for gastrointestinal stroma tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Neoadjuvant imatinib for borderline resectable GIST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: report of a case

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Gastrointestinal stromal tumour treated with neoadjuvant imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Gastrointestinal stromal tumors: key to diagnosis and choice of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Does a lower insulin resistance affect antiviral therapy response in patients suffering from HCV related chronic hepatitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Neoadjuvant therapy with imatinib mesylate for locally advanced GI stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

Efficacy of imatinib mesylate neoadjuvant treatment for a locally advanced rectal gastrointestinal stromal tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3013-7

10.1245/S10434-013-3013-7

21 January 2018

Identifiers

DOI

1 reference

25 March 2018

Dimensions Publication ID

1053346118

0 references

1 reference

25 March 2018